Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder

Larissa J. Mooney, Maureen P. Hillhouse, Christie Thomas, Alfonso Ang, Gaurav Sharma, Garth Terry, Linda Chang, Robrina Walker, Madhukar Trivedi, David Croteau, Steven Sparenborg, Walter Ling

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: This 2-stage open-label pilot study evaluated the safety and potential efficacy of naltrexone + bupropion as a pharmacotherapy for methamphetamine (MA) use disorder. Methods: The study was conducted in 2 stages of recruitment across 3 sites; 20 participants were enrolled in stage 1 and 29 participants were enrolled in stage 2. Eight weeks of open-label pharmacotherapy with a combination of extended-release injectable naltrexone (XR-NTX; Vivitrol) plus extended-release oral bupropion (BRP; Wellbutrin XL) were provided with a smartphone-assisted medication adherence platform. Participants met Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for severe MA use disorder, self-reported ≥20 days of MA use in the 30 days prior to consent, and submitted 3 MA-positive urine drug screens (UDS) out of 4 collected during screening. Participants attended clinic twice weekly for observed BRP dosing, UDS testing, assessments, and medical management; XR-NTX was administered at weeks 1 and 5. A BRP taper and follow-up visit occurred in week 9. Results: Analyses evaluated effects of XR-NTX+BRP to determine the number of "responders" according to a statistically predefined response criterion (6 of 8 MA-negative UDS during the last 4 weeks of medication). The 2-stage design required that stage 1 yield ≥3 responders to continue to stage 2; 11 of the 49 participants met responder criteria across both stages (5 in stage 1, 6 in stage 2). Conclusions: Under the statistical analysis plan, study "success" required ≥9 responders. With 11 responders, the study demonstrated sufficient potential of naltrexone plus bupropion as a combination pharmacotherapy for MA use disorder to warrant further study.

Original languageEnglish (US)
Pages (from-to)236-243
Number of pages8
JournalJournal of Addiction Medicine
Volume10
Issue number4
DOIs
StatePublished - Aug 1 2016

Fingerprint

Bupropion
Naltrexone
Methamphetamine
Safety
Urine
Drug Therapy
Therapeutics
Pharmaceutical Preparations
Medication Adherence
Diagnostic and Statistical Manual of Mental Disorders
Injections

Keywords

  • bupropion
  • extended-release naltrexone
  • medication treatment
  • methamphetamine dependence
  • pharmacotherapy
  • Vivitrol

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. / Mooney, Larissa J.; Hillhouse, Maureen P.; Thomas, Christie; Ang, Alfonso; Sharma, Gaurav; Terry, Garth; Chang, Linda; Walker, Robrina; Trivedi, Madhukar; Croteau, David; Sparenborg, Steven; Ling, Walter.

In: Journal of Addiction Medicine, Vol. 10, No. 4, 01.08.2016, p. 236-243.

Research output: Contribution to journalArticle

Mooney, Larissa J. ; Hillhouse, Maureen P. ; Thomas, Christie ; Ang, Alfonso ; Sharma, Gaurav ; Terry, Garth ; Chang, Linda ; Walker, Robrina ; Trivedi, Madhukar ; Croteau, David ; Sparenborg, Steven ; Ling, Walter. / Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder. In: Journal of Addiction Medicine. 2016 ; Vol. 10, No. 4. pp. 236-243.
@article{878b99cfa9a14762b18caef43504708a,
title = "Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder",
abstract = "Objectives: This 2-stage open-label pilot study evaluated the safety and potential efficacy of naltrexone + bupropion as a pharmacotherapy for methamphetamine (MA) use disorder. Methods: The study was conducted in 2 stages of recruitment across 3 sites; 20 participants were enrolled in stage 1 and 29 participants were enrolled in stage 2. Eight weeks of open-label pharmacotherapy with a combination of extended-release injectable naltrexone (XR-NTX; Vivitrol) plus extended-release oral bupropion (BRP; Wellbutrin XL) were provided with a smartphone-assisted medication adherence platform. Participants met Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for severe MA use disorder, self-reported ≥20 days of MA use in the 30 days prior to consent, and submitted 3 MA-positive urine drug screens (UDS) out of 4 collected during screening. Participants attended clinic twice weekly for observed BRP dosing, UDS testing, assessments, and medical management; XR-NTX was administered at weeks 1 and 5. A BRP taper and follow-up visit occurred in week 9. Results: Analyses evaluated effects of XR-NTX+BRP to determine the number of {"}responders{"} according to a statistically predefined response criterion (6 of 8 MA-negative UDS during the last 4 weeks of medication). The 2-stage design required that stage 1 yield ≥3 responders to continue to stage 2; 11 of the 49 participants met responder criteria across both stages (5 in stage 1, 6 in stage 2). Conclusions: Under the statistical analysis plan, study {"}success{"} required ≥9 responders. With 11 responders, the study demonstrated sufficient potential of naltrexone plus bupropion as a combination pharmacotherapy for MA use disorder to warrant further study.",
keywords = "bupropion, extended-release naltrexone, medication treatment, methamphetamine dependence, pharmacotherapy, Vivitrol",
author = "Mooney, {Larissa J.} and Hillhouse, {Maureen P.} and Christie Thomas and Alfonso Ang and Gaurav Sharma and Garth Terry and Linda Chang and Robrina Walker and Madhukar Trivedi and David Croteau and Steven Sparenborg and Walter Ling",
year = "2016",
month = "8",
day = "1",
doi = "10.1097/ADM.0000000000000218",
language = "English (US)",
volume = "10",
pages = "236--243",
journal = "Journal of Addiction Medicine",
issn = "1932-0620",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Utilizing a two-stage design to investigate the safety and potential efficacy of monthly naltrexone plus once-daily bupropion as a treatment for methamphetamine use disorder

AU - Mooney, Larissa J.

AU - Hillhouse, Maureen P.

AU - Thomas, Christie

AU - Ang, Alfonso

AU - Sharma, Gaurav

AU - Terry, Garth

AU - Chang, Linda

AU - Walker, Robrina

AU - Trivedi, Madhukar

AU - Croteau, David

AU - Sparenborg, Steven

AU - Ling, Walter

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Objectives: This 2-stage open-label pilot study evaluated the safety and potential efficacy of naltrexone + bupropion as a pharmacotherapy for methamphetamine (MA) use disorder. Methods: The study was conducted in 2 stages of recruitment across 3 sites; 20 participants were enrolled in stage 1 and 29 participants were enrolled in stage 2. Eight weeks of open-label pharmacotherapy with a combination of extended-release injectable naltrexone (XR-NTX; Vivitrol) plus extended-release oral bupropion (BRP; Wellbutrin XL) were provided with a smartphone-assisted medication adherence platform. Participants met Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for severe MA use disorder, self-reported ≥20 days of MA use in the 30 days prior to consent, and submitted 3 MA-positive urine drug screens (UDS) out of 4 collected during screening. Participants attended clinic twice weekly for observed BRP dosing, UDS testing, assessments, and medical management; XR-NTX was administered at weeks 1 and 5. A BRP taper and follow-up visit occurred in week 9. Results: Analyses evaluated effects of XR-NTX+BRP to determine the number of "responders" according to a statistically predefined response criterion (6 of 8 MA-negative UDS during the last 4 weeks of medication). The 2-stage design required that stage 1 yield ≥3 responders to continue to stage 2; 11 of the 49 participants met responder criteria across both stages (5 in stage 1, 6 in stage 2). Conclusions: Under the statistical analysis plan, study "success" required ≥9 responders. With 11 responders, the study demonstrated sufficient potential of naltrexone plus bupropion as a combination pharmacotherapy for MA use disorder to warrant further study.

AB - Objectives: This 2-stage open-label pilot study evaluated the safety and potential efficacy of naltrexone + bupropion as a pharmacotherapy for methamphetamine (MA) use disorder. Methods: The study was conducted in 2 stages of recruitment across 3 sites; 20 participants were enrolled in stage 1 and 29 participants were enrolled in stage 2. Eight weeks of open-label pharmacotherapy with a combination of extended-release injectable naltrexone (XR-NTX; Vivitrol) plus extended-release oral bupropion (BRP; Wellbutrin XL) were provided with a smartphone-assisted medication adherence platform. Participants met Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for severe MA use disorder, self-reported ≥20 days of MA use in the 30 days prior to consent, and submitted 3 MA-positive urine drug screens (UDS) out of 4 collected during screening. Participants attended clinic twice weekly for observed BRP dosing, UDS testing, assessments, and medical management; XR-NTX was administered at weeks 1 and 5. A BRP taper and follow-up visit occurred in week 9. Results: Analyses evaluated effects of XR-NTX+BRP to determine the number of "responders" according to a statistically predefined response criterion (6 of 8 MA-negative UDS during the last 4 weeks of medication). The 2-stage design required that stage 1 yield ≥3 responders to continue to stage 2; 11 of the 49 participants met responder criteria across both stages (5 in stage 1, 6 in stage 2). Conclusions: Under the statistical analysis plan, study "success" required ≥9 responders. With 11 responders, the study demonstrated sufficient potential of naltrexone plus bupropion as a combination pharmacotherapy for MA use disorder to warrant further study.

KW - bupropion

KW - extended-release naltrexone

KW - medication treatment

KW - methamphetamine dependence

KW - pharmacotherapy

KW - Vivitrol

UR - http://www.scopus.com/inward/record.url?scp=84982822216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982822216&partnerID=8YFLogxK

U2 - 10.1097/ADM.0000000000000218

DO - 10.1097/ADM.0000000000000218

M3 - Article

VL - 10

SP - 236

EP - 243

JO - Journal of Addiction Medicine

JF - Journal of Addiction Medicine

SN - 1932-0620

IS - 4

ER -